Abstract

Introduction: Different doses of C. Mas concentrated syrup on ascitic tumors was investigated in the Ehrlich Ascites Tumor model (EAT). Material and Methods: A total of 46 Balb/C mice were used in our study, 6 of which were stock animals and the other were in ascitic tumor groups. EAT cells (1×106 EAT cells) were injected intraperitoneally into all of the mice. Mice in the treatment groups with ascitic tumors received 100 mg/kg and 200 mg/kg Cornus Mas extract intraperitoneally for 9 days. Results: Counts after the 3 and 24-hour incubations in the EAT cell line that the average number of the dead cells was less in the group to which 100μg/ml C. Mas was administered when compared with the control group, and that this difference was significant at a statistical level (P<0.05). The purpose was also to determine the in vitro cytotoxic effects of Cornus Mas on EAT cells, to define the alive and dead cell rates, and to compare the 3-hour and 24-hour incubation in groups to which Cornus Mas (syrup) extract were given at different concentrations (50, 100, 250μg/ml). Discussion and Conclusion: EAT model is one of the animal tumors induced empirically, it has been the subject matter of many other studies. In the group in which EAT was applied together with high-dose C. mas fruit syrup, it was observed that the EAT cells were not as intense as they were in the tumor control group. Our study showed the anti-tumor effect of C. Mas in assisted tumor development with EAT cells.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.